Gland Pharma Q3 Results Review - Work In Progress On Multiple Issues: Motilal Oswal
Gland Pharma's Q3 FY23 performance was below our expectation, affected by lower sales across key markets.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Gland Pharma Ltd.’s Q3 FY23 performance was below our expectation, affected by lower sales across key markets due to inventory rationalisation by customers and prolonged supply chain issues.
Gland Pharma has signed a share purchase agreement with Cenexi in Jan-23 and is on track for necessary regulatory approvals for the acquisition. We cut our earnings per share estimates by 10%/12%/11% for FY23/FY24/FY25 and lower the price-to-earnings multiple to 22 times from 24 times to factor in-
lower off-take of Enoxaparin,
the gestation period on account of getting approval for an alternate supplier of stopper for Heparin,
a reduction in business of low-margin products, and
lower pricing of Heparin in India.
Click on the attachment to read the full report:
More Research Reports On Gland Pharma's Q3 FY23 Results Review
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.